Orlando, FL -- (SBWIRE) -- 08/20/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On American Capital Agency Corp. (NASDAQ:AGNC), MannKind Corporation(NASDAQ:MNKD).
American Capital Agency Corp. (NASDAQ:AGNC) shares dropped 6.37% to $20.43. The company on July 29 reported second-quarter net income to shareholders of $1.83 billion or $4.61 per share, compared to a loss of $264 million or $0.88 per share, prior year. Estimated REIT taxable income per common share was $1.04 for the quarter. Comprehensive loss to shareholders for the second quarter of 2013 was $939 million, or $2.37 per common share. Net interest income increased to $414 million, from $384 million last year.
As of June 30, 2013, the Company's net book value per common share was $25.51, or $(3.42) lower than the March 31, 2013 net book value per common share of $28.93, primarily due to wider interest rate spreads in the broader mortgage backed securities market relative to benchmark interest rates such as U.S. Treasury and swap rates.
As of June 30, 2013, the Company's investment portfolio totaled $91.7 billion of agency securities, including $14.5 billion of net TBA mortgage positions, at fair value.
On June 18, 2013, the Board of Directors of the Company declared a second quarter dividend on its common stock of $1.05 per share, compared to $1.25 per share declared in the prior quarter, which was paid on July 26, 2013 to common stockholders of record as of June 28, 2013. Since its May 2008 initial public offering, the Company has paid a total of $3.7 billion in common dividends, or $26.16 per common share.
Are investors worried about the recent updates with AGNC? Find out with a free trend analysis HERE
MannKind Corporation(NASDAQ:MNKD) shares jumped 10.40% to $6.37. The company on August 14 announced positive preliminary results from Study 171, a Phase 3 clinical study of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler), in patients with type 1 diabetes.
Additionally, the company on August 9 reported financial results for the second quarter ended June 30, 2013. The net loss for the second quarter of 2013 was $46.1 million, or $0.16 per share, as compared with a net loss applicable to common stockholders of $36.6 million, or $0.23 per share based on 159.9 million.
Is MNKD going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)